Dyadic International (NASDAQ:DYAI) Announces Earnings Results

Dyadic International (NASDAQ:DYAI) released its earnings results on Wednesday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01), FiscalAI reports. Dyadic International had a negative net margin of 239.67% and a negative return on equity of 695.96%. The business had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.90 million.

Here are the key takeaways from Dyadic International’s conference call:

• Dyadic said it is transitioning from a platform company to a more commercial biotech, with products now launched, shipped, sampled, and beginning to generate revenue through direct sales, OEM distribution, milestone payments, and partnerships.
• Q1 2026 revenue rose 182% year over year to about $1.1 million, driven largely by higher R&D and grants-related activity, while the net loss improved modestly to about $1.95 million.
• The company highlighted multiple commercialization wins, including Proliant’s launch of AlbuFree DX, Enzymes’ commercial launch of recombinant bovine chymosin, and first commercial shipments of DNase I and transferrin through its IBT Bioservices distribution agreement.
• Management said customer interest is increasing across life sciences, food and nutrition, and industrial markets, including initial purchase orders in cultivated meat and expanded sampling in Asia-Pacific and Europe through partners like Intralink and FermBox Bio.
• Dyadic ended the quarter with about $6.6 million in cash, restricted cash, and investment-grade securities, and management reiterated that existing resources should fund operations into Q2 2027 if cash burn stays near recent levels.

Dyadic International Price Performance

Shares of NASDAQ DYAI traded down $0.01 during mid-day trading on Wednesday, hitting $0.71. 124,868 shares of the stock traded hands, compared to its average volume of 70,427. The company has a market cap of $25.89 million, a PE ratio of -2.84 and a beta of 1.18. Dyadic International has a twelve month low of $0.65 and a twelve month high of $1.35. The firm has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $0.88. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.68 and a quick ratio of 2.68.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DYAI. Landscape Capital Management L.L.C. acquired a new position in Dyadic International during the 3rd quarter worth about $190,000. Geode Capital Management LLC lifted its holdings in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the period. Finally, Bank of America Corp DE lifted its holdings in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the period. 27.95% of the stock is owned by institutional investors and hedge funds.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.